Induction of delayed hypersensitivity reactions in cancer patients by cholesterol-hemisuccinate-treated autologous tumor cells

Y. Skornick, A. R. Dresdale, W. F. Sindelar

Research output: Contribution to journalArticlepeer-review

Abstract

Cholesterol-hemisuccinate (CHS) incorporated into tumor cells increases membrane lipid microviscosity and confers enhanced immunogenicity, which can be manifested by delayed hypersensitivity skin reactions. Skin testing was performed in 30 patients with various advanced malignant tumors. Patients were given intradermal injections of 106 autologous, irradiated, CHS-treated tumor cells. Control injections consisted of untreated irradiated tumor cells. CHS-treated autologous normal peripheral lymphocytes, or CHS-treated autologous normal tissues. For all patients tested, strongly positive skin reactions were observed when CHS-treated tumor cells were used. Untreated irradiated cells gave negative or very weakly positive reactions. In all cases, normal CHS-treated cells did not elicit any observable skin reactions. CHS-treated cells may have unmasked tumor-associated antigens to which patients may elicit immunologic responses.

Original languageEnglish
Pages (from-to)465-467
Number of pages3
JournalJournal of the National Cancer Institute
Volume70
Issue number3
StatePublished - 1983
Externally publishedYes

Fingerprint

Dive into the research topics of 'Induction of delayed hypersensitivity reactions in cancer patients by cholesterol-hemisuccinate-treated autologous tumor cells'. Together they form a unique fingerprint.

Cite this